Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802163 | 0.85 | P2RX7 (0.67) | P2RX7HSD11B1KCNN4POLB | |
| SCHEMBL5801683 | 0.84 | P2RX7 (0.71) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL5810456 | 0.83 | P2RX7 (0.74) | P2RX7HSD11B1KCNN4NR1H2NR1H3 | |
| SCHEMBL5917661 | 0.80 | P2RX7 (0.64) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL5917600 | 0.79 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL5816902 | 0.79 | P2RX7 (0.67) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL5810445 | 0.78 | P2RX7 (0.51) | P2RX7NR1H2NR1H3 | |
| SCHEMBL6361666 | 0.76 | P2RX7 (0.58) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL5810224 | 0.74 | P2RX7 (0.63) | P2RX7HSD11B1KCNN4POLB | |
| SCHEMBL5801354 | 0.74 | P2RX7 (1.00) | P2RX7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | claimed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | P2RX7 3/4885HSD11B1 2603/4885KCNN4 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.